Pocket Size Handheld ADSL2+ Tester for ADSL, ADSL2, ADSL2+ and Re-ADSL Testing

Toronto, Canada - GAO Instruments (www.GAOInstruments.com) is offering its pocket size handheld ADSL2+ tester. It is an ideal tool for ADSL/ADSL2+ network installation, maintenance and fault elimination. This multi-function ADSL2+ tester, model A0010007, features easy menu operation, ISP login, IP Ping tests, auto shut off function and audio and LED alarm indications. It performs xDSL line testing for ADSL, ADSL2, ADSL2+ and Re-ADSL. Aside from providing xDSL and dial testing, the tester also functions as a digital multi-meter (DMM). It also provides modem emulation, telephone call functions and line voltage indication. This handheld ADSL2+ tester is compliant with all known DSLAMs. It has a memory capacity to store up to 50 records. It communicates with a computer through an RS232 interface. In addition, its internal rechargeable 2800 mAH Li-Ion battery allows for 4 to 5 hours of continuous operation. This pocket size handheld ADSL2+ tester belongs to GAO's family of ADSL Testers. This line includes a wide variety of testers such as portable ADSL2+ tester which has been widely used by ADSL business operators and Multi-function Handheld xDSL Tester which is designed to test and analyze VDSL2, ADSL, ADSL2 and ADSL2+ networks. This line also includes other similar ADSL testers such as Portable xDSL Tester and Multi-function ADSL/ADSL2+ Tester. For sales inquiries please contact: 1-877 585-9555 ext. 601 - Toll Free (USA & Canada) 1-416 292-0038 ext. 601 - All Other Areas [email protected] About GAO Instruments GAO Instruments (www.GAOInstruments.com) is an international leading supplier of portable testing instruments and equipment for telecom, fiber, oscilloscope, electronic.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.